oxepinac

non-steroidal anti-inflammatory drug; RN given refers to parent cpd; structure in first source & Negwer, 5th ed, #6399

Also Known As:

6,7-dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid; DD-3314; oxepinac monosodium salt; dibenz(b,e)oxepin-3-acetic acid, 6,11-dihydro-11-oxo-

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

1.	Ulcer 01/01/1978 - "Long-term study in rats revealed that oxepinac produced no hematological, blood chemical and pathological changes except for minor anemia and fatal ulcer formation occurring predominantly in females. "
2.	Osteoarthritis 01/01/1978 - "It is concluded that oxepinac offers an effective and well-tolerated alternative to drugs at present being used in the treatment of painful osteoarthritis." 01/01/1978 - "Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis." 01/01/1978 - "Clinical evaluation in phase II of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid (oxepinac) has been made in a single-blind trial in the treatment of osteoarthritis, 135 patients with mainly gonitis. "
3.	Anemia 01/01/1978 - "Long-term study in rats revealed that oxepinac produced no hematological, blood chemical and pathological changes except for minor anemia and fatal ulcer formation occurring predominantly in females. "
4.	Pain (Aches) 01/01/1978 - "Oxepinac resulted in definite relief of pain compared with preceding medication and was tolerated well without serious side effect. "
5.	Joint Diseases (Joint Disease) 01/01/1978 - "Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis."